Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032
일본의 단백질 치료제 시장 규모는 2023년 284억 달러로 추정됩니다. 향후 IMARC 그룹은 2032년까지 시장 규모가 527억 달러에 달하고, 2024년부터 2032년까지 6.60%의 연평균 성장률(CAGR)을 나타낼 것으로 예측했습니다. 암, 당뇨병, 자가면역질환과 같은 만성질환의 발병률 증가와 표적화된 효과적인 치료를 제공하는 단백질 치료제에 대한 수요 증가가 시장을 주도하고 있습니다.
본 보고서에서 다룬 주요 질문
- 일본의 단백질 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 발전할 것인가?
- 코로나19가 일본 단백질 치료제 시장에 미치는 영향은?
- 일본 단백질 치료제 시장의 제품별 구성비는?
- 일본 단백질 치료제 시장의 치료 영역별 분석은?
- 일본 단백질 치료제 시장의 기능별 분류는?
- 일본 단백질 치료제 시장의 밸류체인에는 어떤 단계가 있는가?
- 일본 단백질 치료제의 주요 촉진요인과 과제는?
- 일본 단백질 치료제 시장의 구조와 주요 기업은?
- 일본 단백질 치료제 시장에서의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 일본의 단백질 치료제 시장 : 서론
제5장 일본의 단백질 치료제 시장 구도
- 과거 및 현재 시장 동향(2018-2023년)
- 시장 예측(2024-2032년)
제6장 일본의 단백질 치료제 시장 : 제품별 분석
- 단클론항체(mAbs)
- 인간 인슐린
- 에리스로포이에틴
- 응고인자
- 융합 단백질
- 기타
제7장 일본의 단백질 치료제 시장 : 치료 영역별 분석
- 대사장애
- 면역질환
- 혈액질환
- 암
- 호르몬 장애
- 유전성 질환
- 기타
제8장 일본의 단백질 치료제 시장 : 기능별 분석
- 효소 및 조절 활성
- 특별 표적 활동
- 백신
- 단백질 진단
제9장 일본의 단백질 치료제 시장 : 경쟁 구도
- 개요
- 시장 구조
- 시장 기업 포지셔닝
- 주요 성공 전략
- 경쟁 대시보드
- 기업 평가 상한
제10장 주요 기업 개요
제11장 일본의 단백질 치료제 시장 : 업계 분석
- 성장 촉진요인 및 억제요인과 기회
- Porter의 Five Forces 분석
- 밸류체인 분석
제12장 부록
LSH
Japan protein therapeutics market size reached US$ 28.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.60% during 2024-2032. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.
Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.
Japan Protein Therapeutics Market Trends:
The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.
Japan Protein Therapeutics Market Segmentation:
Product Insights:
- Monoclonal Antibodies (mAbs)
- Human Insulin
- Erythropoietin
- Clotting Factors
- Fusion Protein
- Others
Therapy Area Insights:
- Metabolic Disorders
- Immunological Disorders
- Hematological Disorders
- Cancer
- Hormonal Disorders
- Genetic Disorders
- Others
Function Insights:
- Enzymatic and Regulatory Activity
- Special Targeting Activity
- Vaccines
- Protein Diagnostics
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Key Questions Answered in This Report:
- How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan protein therapeutics market?
- What is the breakup of the Japan protein therapeutics market on the basis of product?
- What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
- What is the breakup of the Japan protein therapeutics market on the basis of function?
- What are the various stages in the value chain of the Japan protein therapeutics market?
- What are the key driving factors and challenges in the Japan protein therapeutics?
- What is the structure of the Japan protein therapeutics market and who are the key players?
- What is the degree of competition in the Japan protein therapeutics market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Japan Protein Therapeutics Market - Introduction
- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence
5 Japan Protein Therapeutics Market Landscape
- 5.1 Historical and Current Market Trends (2018-2023)
- 5.2 Market Forecast (2024-2032)
6 Japan Protein Therapeutics Market - Breakup by Product
- 6.1 Monoclonal Antibodies (mAbs)
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2018-2023)
- 6.1.3 Market Forecast (2024-2032)
- 6.2 Human Insulin
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2018-2023)
- 6.2.3 Market Forecast (2024-2032)
- 6.3 Erythropoietin
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2018-2023)
- 6.3.3 Market Forecast (2024-2032)
- 6.4 Clotting Factors
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2018-2023)
- 6.4.3 Market Forecast (2024-2032)
- 6.5 Fusion Protein
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2018-2023)
- 6.5.3 Market Forecast (2024-2032)
- 6.6 Others
- 6.6.1 Historical and Current Market Trends (2018-2023)
- 6.6.2 Market Forecast (2024-2032)
7 Japan Protein Therapeutics Market - Breakup by Therapy Area
- 7.1 Metabolic Disorders
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2018-2023)
- 7.1.3 Market Forecast (2024-2032)
- 7.2 Immunological Disorders
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2018-2023)
- 7.2.3 Market Forecast (2024-2032)
- 7.3 Hematological Disorders
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2018-2023)
- 7.3.3 Market Forecast (2024-2032)
- 7.4 Cancer
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2018-2023)
- 7.4.3 Market Forecast (2024-2032)
- 7.5 Hormonal Disorders
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2018-2023)
- 7.5.3 Market Forecast (2024-2032)
- 7.6 Genetic Disorders
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2018-2023)
- 7.6.3 Market Forecast (2024-2032)
- 7.7 Others
- 7.7.1 Historical and Current Market Trends (2018-2023)
- 7.7.2 Market Forecast (2024-2032)
8 Japan Protein Therapeutics Market - Breakup by Function
- 8.1 Enzymatic and Regulatory Activity
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2018-2023)
- 8.1.3 Market Forecast (2024-2032)
- 8.2 Special Targeting Activity
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2018-2023)
- 8.2.3 Market Forecast (2024-2032)
- 8.3 Vaccines
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2018-2023)
- 8.3.3 Market Forecast (2024-2032)
- 8.4 Protein Diagnostics
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2018-2023)
- 8.4.3 Market Forecast (2024-2032)
9 Japan Protein Therapeutics Market - Competitive Landscape
- 9.1 Overview
- 9.2 Market Structure
- 9.3 Market Player Positioning
- 9.4 Top Winning Strategies
- 9.5 Competitive Dashboard
- 9.6 Company Evaluation Quadrant
10 Profiles of Key Players
- 10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Product Portfolio
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
- 10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Product Portfolio
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
- 10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Product Portfolio
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
- 10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Product Portfolio
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
- 10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Product Portfolio
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events
11 Japan Protein Therapeutics Market - Industry Analysis
- 11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
- 11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
- 11.3 Value Chain Analysis
12 Appendix
